share_log

Coeptis Therapeutics to Present Its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

Coeptis Therapeutics to Present Its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

Coeptis Therapeutics 将在 2024 年 ISCT 上展示其通用同种异体 SNAP-CAR NK 细胞疗法
Coeptis Therapeutics ·  05/08 00:00

WEXFORD, Pa., May 8, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced today that the Company has been selected for an oral presentation of the abstract titled Developing A First-In-Class Universal Allogeneic Snap-Car NK Cell Therapy at the International Society for Cell & Gene Therapy 2024, being held May 28th to June 1st in Vancouver, Canada.

宾夕法尼亚州韦克斯福德,2024 年 5 月 8 日/PRNewswire/— Coeptis Therapeutics Holdings, Inc.(纳斯达克股票代码:COEP)(“公司” 或 “Coeptis”)是一家为癌症、自身免疫和传染病开发创新细胞疗法平台的生物制药公司,今天宣布,该公司已被选为该摘要的口头陈述 开发一流的通用异基因 Snap-Car NK 细胞疗法 在5月28日举行的2024年国际细胞与基因疗法学会上第四 至 6 月 1 日st 在加拿大温哥华。

The Company's SNAP-CAR platform technology has demonstrated its potential as a "universal" CAR therapy with the potential to target multiple antigens through combinatorial use of different adaptors, thus potentially avoiding toxicities and relapse due to antigen loss. In Q3 of 2023, Coeptis expanded its exclusive license agreement with the University of Pittsburgh for SNAP-CAR to include natural killer (NK) cells.

该公司的SNAP-CAR平台技术已证明其作为 “通用” CAR疗法的潜力,有可能通过组合使用不同的适配器来靶向多种抗原,从而有可能避免因抗原流失而产生毒性和复发。2023年第三季度,Coeptis扩大了与匹兹堡大学签订的SNAP-CAR独家许可协议,将自然杀伤(NK)细胞包括在内。

The background and aim of the abstract revolve around chimeric antigen receptor (CAR) expression by engineered NK cells and the ability to improve their innate anti-tumor functions by specifically activating NK cells in the presence of tumor antigen. Backed by research performed in conjunction with the University of Pittsburgh and Deverra Therapeutics, allogeneic CAR NK cells may be a safer, more clinically accessible, and cost-effective cellular therapy than autologous CAR T-cells. Based on the demonstrated successful use of a novel SNAP-CAR technology in T-cells, the Company is developing a first-in-class universal allogeneic SNAP-CAR NK cell. This product replaces the antigen binding domain of a CAR with a SNAP tag enzyme that carries out a self-labeling reaction to covalently attach any antibody conjugated to a benzylguanine (BG) tag to create a functional antigen-specific CAR.

摘要的背景和目标围绕工程化NK细胞的嵌合抗原受体(CAR)表达,以及在存在肿瘤抗原的情况下通过特异性激活NK细胞来改善其与生俱来的抗肿瘤功能的能力。在匹兹堡大学和Deverra Therapeutics联合开展的研究的支持下,与自体CAR T细胞相比,异体CAR NK细胞可能是一种更安全、更具临床可及性和成本效益的细胞疗法。基于已证明在T细胞中成功使用一种新型SNAP-CAR技术,该公司正在开发同类首款通用异体SNAP-CAR NK细胞。该产品用 SNAP 标签酶取代 CAR 的抗原结合域,该酶进行自标记反应,将任何与苯甲鸟嘌呤 (BG) 标签偶联的抗体共价附着,从而产生功能性抗原特异性 CAR。

"ISCT 2024 is a prestigious gathering renowned for fostering groundbreaking ideas and innovation," said Dave Mehalick, President and CEO of Coeptis Therapeutics. "Our presentation represents a significant and meaningful path forward in advancing our mission to develop a proprietary, allogeneic cell generation platform aimed at universalizing the treatment of many debilitating diseases."

Coeptis Therapeutics总裁兼首席执行官戴夫·梅哈利克表示:“ISCT 2024是一次享有盛誉的会议,以促进开创性的想法和创新而闻名。”“我们的演讲代表了推进我们开发专有异基因细胞生成平台的使命的重要而有意义的前进道路,该平台旨在普及许多使人衰弱的疾病的治疗。”

Details of the presentations are outlined below:

演讲的细节概述如下:

TITLE: DEVELOPING A FIRST-IN-CLASS UNIVERSAL ALLOGENEIC SNAP-CAR NK CELL

标题: 开发出同类首创的通用异基因 SNAP-CAR NK 细胞

PRESENTATION TYPE: Oral, Thursday, May 30, 2024 at 8am

演示文稿类型: 口服,2024 年 5 月 30 日星期四上午 8 点

AUTHORS: Carrie Stoltzman, Erika von Euw, Braxton Jamison (presenting author), Emily Hsieh, Kevin Green, Lara Ionescu Silverman, Dan Yerace, Dave Mehalick, Colleen Delaney

作者: Carrie Stoltzman、Erika von Euw、Braxton Jamison(主持作者)、Emily Hsieh、Kevin Green、Lara Ionescu Silverman、Dan Yerace、Dave Mehalick、Colleen Delaney

INSTITUTIONS: Deverra Therapeutics, Seattle, WA, United States

机构: Deverra Therapeutics,美国华盛顿州西雅图

Coeptis Therapeutics, Wexford, PA, United States

Coeptis 疗法美国宾夕法尼亚州韦克斯福德

The International Symposium on Cell and Gene Therapy (ISCT) brings together leading researchers, clinicians and industry experts in cell and gene therapy from around the world. Serving as a nexus for collaboration, the conference promotes the exchange of new scientific advances, technological advances and clinical insights in the rapidly developing field of cell and gene therapy. For more information: www.isctglobal.org/isct2024.

国际细胞与基因疗法研讨会(ISCT)汇集了来自世界各地的细胞和基因疗法领域的领先研究人员、临床医生和行业专家。作为合作的纽带,该会议促进了快速发展的细胞和基因疗法领域的新科学进展、技术进步和临床见解的交流。欲了解更多信息: www.isctglobal.org/isct2024

About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer and infectious diseases. The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/.

关于 Coeptis Therapeutics Holdings
Coeptis Therapeutics Holdings, Inc. 及其子公司,包括Coeptis Therapeutics, Inc.和Coeptis Pharmicals, Inc.(统称 “Coeptis”),是一家生物制药公司,为癌症、自身免疫和传染病开发创新的细胞治疗平台,这些平台有可能颠覆传统治疗模式并改善患者预后。Coeptis的产品组合和权利以Deverra Therapeutics许可的资产为重点,包括异基因细胞免疫疗法平台和临床阶段、未经修改的自然杀伤细胞疗法技术 DVX201。此外,Coeptis正在开发一种获得匹兹堡大学(SNAP-CAR)许可的通用多抗原CAR T技术,以及GEAR细胞疗法和伴随诊断平台,Coeptis正在与Vygen-bio和卡罗林斯卡研究所的领先医学研究人员共同开发该平台。Coeptis的商业模式旨在通过许可协议、外包许可协议和共同开发关系最大化其当前产品组合和权利的价值,以及建立战略合作伙伴关系以扩大其产品权利和供应,特别是针对癌症和传染病的产品权利和供应。该公司总部位于宾夕法尼亚州韦克斯福德。有关 Coeptis 的更多信息,请访问 https://coeptistx.com/

Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (5) costs related to integrating the newly-licensed Deverra assets and pursuing the contemplated asset development paths; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (8) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.

关于前瞻性陈述的警示说明
本新闻稿以及我们管理层就此发表的声明包含或可能包含 “前瞻性陈述”(定义见经修订的1933年《证券法》第27A条和经修订的1934年《证券交易法》第21E条)。前瞻性陈述包括有关我们的计划、目的、目标、战略、未来事件或业绩以及基本假设的陈述,以及除历史事实陈述之外的其他陈述。当我们使用诸如 “可能”、“将”、“打算”、“应该”、“相信”、“期望”、“预期”、“项目”、“估计” 之类的词语或不完全与历史问题相关的类似表达方式时,我们是在做出前瞻性陈述。前瞻性陈述并不能保证未来的业绩,涉及重大风险和不确定性,可能导致实际业绩与我们在前瞻性陈述中讨论的预期存在重大差异,甚至可能存在重大差异。可能导致此类差异的因素包括但不限于:(1)无法维持公司证券在纳斯达克资本市场的上市;(2)整合Deverra许可资产有可能扰乱公司当前的计划和运营;(3)无法确认新许可资产的预期收益,这可能会受到竞争、公司增长和增长能力等因素的影响经济地管理增长,雇用和留住关键员工;(4)风险公司在开发的产品或新许可的资产未通过临床试验或未获得美国食品药品监督管理局或其他适用的监管机构的批准;(5)与整合新许可的Deverra资产和追求设想的资产开发道路有关的成本;(6)适用法律或法规的变化;(7)公司可能受到其他经济、商业和/或竞争因素的不利影响;以及(8)的影响全球 COVID-19 疫情对上述任何风险及其他公司向美国证券交易委员会(“SEC”)提交的文件中发现的风险和不确定性。上述因素清单并不是排他性的。所有前瞻性陈述都存在重大的不确定性和风险,包括但不限于公司向美国证券交易委员会提交的报告和其他文件中包含或将包含的风险。出于这些原因,除其他外,提醒投资者不要过分依赖本新闻稿中的任何前瞻性陈述。公司向美国证券交易委员会提交或将要提交的文件中讨论了其他因素,这些文件可在以下网址查阅 www.sec.gov。除非适用的法律、法规或规则要求,否则我们没有义务公开修改这些前瞻性陈述以反映本陈述发布之日之后发生的事件或情况。

Contacts
Coeptis Therapeutics, Inc.
IR@coeptistx.com

联系人
Coeptis Therapeutics, Inc
IR@coeptistx.com

SOURCE Coeptis Therapeutics, Inc.

来源 Coeptis Therapeutics, Inc.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发